Inhibitors of GSK-3 proteins are being developed as potential therapeutics for numerous conditions, including bipolar disorder, Alzheimer's disease, and diabetes. However, new research in mice indicates that these drugs might have adverse effects on the heart, suggesting that the risk/benefit assessment of such drugs might need to be considered carefully.